The Latin America, Middle East and Africa Arteriovenous Fistula Devices Market should witness market growth of 11.2% CAGR during the forecast period (2023-2030).
Arteriovenous malformations (AVM), also known as AVF, are currently being treated by endovascular embolization. A catheter is inserted via the groin into the brain arteries that contributes to the AVM during this treatment, and a substance is injected into the arteries. The artery is blocked by this injection, which reduces blood supply to the AVM. Endovascular embolization is nearly always employed as a first step in either microsurgical excision or stereotactic radiotherapy preparation since it typically does not eliminate the AVM on its own.
Businesses involved in the market are now more involved with launching strategies like corporate social responsibility (CSR) programs, targeted marketing, etc. Additionally, the rising efforts to increase awareness of the availability of such devices because AVF devices offer many benefits. Since there is no foreign material present, unlike a catheter implanted for dialysis, which can provide a direct channel for infection to reach the body, infection rates are lower. For the best dialysis sessions, higher blood flow rates can be provided by AVFs. It also results in fewer instances of clot formation or thrombosis.
According to research looking at the prevalence of CKD, diabetes mellitus has become the primary risk factor for CKD in this region. The Saudi Medical Journal reports that between 2002 and 2018, a different study evaluated the prevalence of type 2 diabetes mellitus (T2DM) among females in Arab nations. Belize has seen the biggest increase (10 percentage points), whereas the incidence in Venezuela and Uruguay fell by about 6 percentage points between 2010 and 2019. Therefore, the rising prevalence of diabetes mellitus will lead to an increase in kidney disease, thereby propelling the expansion of the market.
The Brazil market dominated the LAMEA Arteriovenous Fistula Devices Market by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $10.4 million by 2030. The Argentina market is poised to grow at a CAGR of 11.8% during (2023-2030). Additionally, The UAE market would exhibit a CAGR of 10.9% during (2023-2030).
Based on End-use, the market is segmented into Hospitals, Ambulatory Surgical Centers and Dialysis Centers. Based on Type, the market is segmented into AVF Creation Devices (Surgical Instruments, Vascular Grafts, Angioplasty Balloons and Others), AVF Monitoring Devices (Doppler Ultrasound, Pressure Monitoring Systems, and Others) and AVF Maintenance Devices (Central Venous Catheters, Stents and Others). Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Medtronic PLC, Becton, Dickinson and Company, Teleflex, Inc., Fresenius Medical Care AG & Co. KGaA. (Fresenius SE & Co. KGaA), B. Braun Melsungen AG, Poly Medicure Ltd., Asahi Kasei Corporation, Laminate Medical Technologies Ltd., Cook Medical, Inc. (Cook Group), and Boston Scientific Corporation
Arteriovenous malformations (AVM), also known as AVF, are currently being treated by endovascular embolization. A catheter is inserted via the groin into the brain arteries that contributes to the AVM during this treatment, and a substance is injected into the arteries. The artery is blocked by this injection, which reduces blood supply to the AVM. Endovascular embolization is nearly always employed as a first step in either microsurgical excision or stereotactic radiotherapy preparation since it typically does not eliminate the AVM on its own.
Businesses involved in the market are now more involved with launching strategies like corporate social responsibility (CSR) programs, targeted marketing, etc. Additionally, the rising efforts to increase awareness of the availability of such devices because AVF devices offer many benefits. Since there is no foreign material present, unlike a catheter implanted for dialysis, which can provide a direct channel for infection to reach the body, infection rates are lower. For the best dialysis sessions, higher blood flow rates can be provided by AVFs. It also results in fewer instances of clot formation or thrombosis.
According to research looking at the prevalence of CKD, diabetes mellitus has become the primary risk factor for CKD in this region. The Saudi Medical Journal reports that between 2002 and 2018, a different study evaluated the prevalence of type 2 diabetes mellitus (T2DM) among females in Arab nations. Belize has seen the biggest increase (10 percentage points), whereas the incidence in Venezuela and Uruguay fell by about 6 percentage points between 2010 and 2019. Therefore, the rising prevalence of diabetes mellitus will lead to an increase in kidney disease, thereby propelling the expansion of the market.
The Brazil market dominated the LAMEA Arteriovenous Fistula Devices Market by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $10.4 million by 2030. The Argentina market is poised to grow at a CAGR of 11.8% during (2023-2030). Additionally, The UAE market would exhibit a CAGR of 10.9% during (2023-2030).
Based on End-use, the market is segmented into Hospitals, Ambulatory Surgical Centers and Dialysis Centers. Based on Type, the market is segmented into AVF Creation Devices (Surgical Instruments, Vascular Grafts, Angioplasty Balloons and Others), AVF Monitoring Devices (Doppler Ultrasound, Pressure Monitoring Systems, and Others) and AVF Maintenance Devices (Central Venous Catheters, Stents and Others). Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Medtronic PLC, Becton, Dickinson and Company, Teleflex, Inc., Fresenius Medical Care AG & Co. KGaA. (Fresenius SE & Co. KGaA), B. Braun Melsungen AG, Poly Medicure Ltd., Asahi Kasei Corporation, Laminate Medical Technologies Ltd., Cook Medical, Inc. (Cook Group), and Boston Scientific Corporation
Scope of the Study
By End-use
- Hospitals
- Ambulatory Surgical Centers
- Dialysis Centers
By Type
- AVF Creation Devices
- Surgical Instruments
- Vascular Grafts
- Angioplasty Balloons
- Others
- AVF Monitoring Devices
- Doppler Ultrasound
- Pressure Monitoring Systems
- Others
- AVF Maintenance Devices
- Central Venous Catheters
- Stents
- Others
By Country
- Brazil
- Argentina
- UAE
- Saudi Arabia
- South Africa
- Nigeria
- Rest of LAMEA
Key Market Players
List of Companies Profiled in the Report:
- Medtronic PLC
- Becton, Dickinson and Company
- Teleflex, Inc.
- Fresenius Medical Care AG & Co. KGaA. (Fresenius SE & Co. KGaA)
- B.Braun Melsungen AG
- Poly Medicure Ltd.
- Asahi Kasei Corporation
- Laminate Medical Technologies Ltd.
- Cook Medical, Inc. (Cook Group)
- Boston Scientific Corporation
Unique Offerings
- Exhaustive coverage
- The highest number of Market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market at a Glance
Chapter 3. Market Overview
Chapter 4. LAMEA Arteriovenous Fistula Devices Market by End-use
Chapter 5. LAMEA Arteriovenous Fistula Devices Market by Type
Chapter 6. LAMEA Arteriovenous Fistula Devices Market by Country
Chapter 7. Company Profiles
Companies Mentioned
- Medtronic PLC
- Becton, Dickinson and Company
- Teleflex, Inc.
- Fresenius Medical Care AG & Co. KGaA. (Fresenius SE & Co. KGaA)
- B. Braun Melsungen AG
- Poly Medicure Ltd.
- Asahi Kasei Corporation
- Laminate Medical Technologies Ltd.
- Cook Medical, Inc. (Cook Group)
- Boston Scientific Corporation
Methodology
LOADING...
